Hammarskiöld advised Linc AB (publ) (“Linc”), a leading Nordic life science investor, in connection with its IPO on Nasdaq Stockholm. Skandinaviska Enskilda Banken AB (publ) (“SEB”) acted as Global Coordinator and Joint Bookrunner in connection with the IPO and ABG Sundal Collier acted as Joint Bookrunner. SEB and Avanza Bank AB (publ) acted as Retail Distributors in connection with the IPO.
Linc was founded in 1991 by the main owner and chairman of the board, Bengt Julander, and is an investor in product-oriented companies in the Nordic life science industry. The company is mainly focused on investing in and developing small and medium-sized life science companies with global potential in the medical technology and pharmaceutical industries. Investments are made in both private and public companies, as well as in pre-clinical/clinical-stage companies and companies with established business operations.
Hammarskiöld’s team mainly consisted of:
Carl-Johan Pousette (Partner)
Marcus Tipner (Associate)
Aksel Ahlqvist (Associate)